Variant · Snv

FGFR3 G370C

CI-VAR-00001726Explore in graph →NP_000133.1:p.Gly370CysNM_000142.5:c.1108G>TClinVar 16359 CIViC 2406 rs121913479

Curated evidence

Evidence by cancer (15 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–15 of 15 evidence items across 7 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Carcinoma1
FGFR3 S249C AND FGFR3 R248C AND FGFR3 Y373C AND FGFR3 G370C	Erdafitinib	Predictive	A	Supports Sensitivity Response	4	rejected	EID11259 In this open-label, phase II trial, 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma with various FGFR alterations who had a history of disease progression during … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC	civic
Bladder Urothelial Carcinoma2
FGFR3 G370C	(oncogenic)	Oncogenic	C	Supports Oncogenicity	3	submitted	EID13142 In a pan-cancer analysis of 10,967 TCGA tumor samples across 32 cancer types, FGFR3 G370C was identified in 5 bladder urothelial carcinoma samples and was classified as an oncogenic FGFR3 mutation. G3… (full text at CIViC)

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
16359	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Thanatophoric dysplasia type 1; Epidermal nevus; Thanatophoric dysplasia; Achondroplasia; Neoplasm; FGFR3-related disorder; FGFR3-related chondrodysplasia	germline/somatic	15	Jun 23, 2026	clinvar

Malignant Neoplasm5
FGFR3 G370C	(oncogenic)	Oncogenic	C	Supports Oncogenicity	3	submitted	EID13143 In a targeted next-generation sequencing analysis of 4,853 solid tumors, FGFR3 G370C was identified as a somatic mutation in 3 cases: one cutaneous squamous cell carcinoma, one non-small cell lung car… (full text at CIViC) PMID 26373574 · Helsten et al., 2016 · Open in CIViC	civic
FGFR3 G370C	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID12843 The extracellular/transmembrane domain mutation G370C was tested in a series of assays for an evaluation of oncogenicity. G370C was stably transfected into 3T3 cells along with WT controls. TAS (Tra… (full text at CIViC) PMID 34272467 · Nakamura et al., 2021 · Open in CIViC	civic
FGFR3 G370C	Erdafitinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID13175 In a preclinical MANO drug-sensitivity assay, 3T3 cells expressing FGFR3 G370C were treated with erdafitinib for 5 days. Erdafitinib inhibited the viability of FGFR3 G370C-expressing cells with an est… (full text at CIViC) PMID 34272467 · Nakamura et al., 2021 · Open in CIViC	civic
FGFR3 G370C	Infigratinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID13174 In a preclinical MANO drug-sensitivity assay, 3T3 cells expressing FGFR3 G370C were treated with infigratinib for 5 days. Infigratinib inhibited FGFR3 G370C-expressing cells with an estimated IC50 of … (full text at CIViC) PMID 34272467 · Nakamura et al., 2021 · Open in CIViC	civic
FGFR3 G370C	R3Mab	Predictive	D	Does Not Support Resistance	3	accepted	EID10353 Ba/F3 cells transfected with wild type FGFR3 or common bladder carcinoma variant FGFR3 G372C both resulted in IL-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment wit… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic

Malignant Neoplasm5

FGFR3 G370C

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID13143

In a targeted next-generation sequencing analysis of 4,853 solid tumors, FGFR3 G370C was identified as a somatic mutation in 3 cases: one cutaneous squamous cell carcinoma, one non-small cell lung car… (full text at CIViC)

PMID 26373574 · Helsten et al., 2016 · Open in CIViC

civic

FGFR3 G370C

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID12843

The extracellular/transmembrane domain mutation G370C was tested in a series of assays for an evaluation of oncogenicity. G370C was stably transfected into 3T3 cells along with WT controls. TAS (Tra… (full text at CIViC)

PMID 34272467 · Nakamura et al., 2021 · Open in CIViC

civic

FGFR3 G370C

Erdafitinib

Predictive

Supports Sensitivity Response

submitted

EID13175

In a preclinical MANO drug-sensitivity assay, 3T3 cells expressing FGFR3 G370C were treated with erdafitinib for 5 days. Erdafitinib inhibited the viability of FGFR3 G370C-expressing cells with an est… (full text at CIViC)

PMID 34272467 · Nakamura et al., 2021 · Open in CIViC

civic

FGFR3 G370C

Infigratinib

Predictive

Supports Sensitivity Response

submitted

EID13174

In a preclinical MANO drug-sensitivity assay, 3T3 cells expressing FGFR3 G370C were treated with infigratinib for 5 days. Infigratinib inhibited FGFR3 G370C-expressing cells with an estimated IC50 of … (full text at CIViC)

PMID 34272467 · Nakamura et al., 2021 · Open in CIViC

civic

FGFR3 G370C

R3Mab

Predictive

Does Not Support Resistance

accepted

EID10353

Ba/F3 cells transfected with wild type FGFR3 or common bladder carcinoma variant FGFR3 G372C both resulted in IL-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment wit… (full text at CIViC)

PMID 19381019 · Qing et al., 2009 · Open in CIViC

civic

Transitional Cell Carcinoma2
FGFR3 G370C	Erdafitinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID7307 Patients with metastatic or unresectable urothelial carcinoma havoring FGFR2 fusion, FGFR3 fusion or FGFR3 mutation were treated with pan-FGFR inhibitor, erdafitinib, in Phase 2 trial. 96 patients wer… (full text at CIViC) Open in CIViC	civic
FGFR3 G370C	Infigratinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID6414 In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC	civic

Transitional Cell Carcinoma2

FGFR3 G370C

Erdafitinib

Predictive

Supports Sensitivity Response

submitted

EID7307

Patients with metastatic or unresectable urothelial carcinoma havoring FGFR2 fusion, FGFR3 fusion or FGFR3 mutation were treated with pan-FGFR inhibitor, erdafitinib, in Phase 2 trial. 96 patients wer… (full text at CIViC)

Open in CIViC

civic

FGFR3 G370C

Infigratinib

Predictive

Supports Sensitivity Response

submitted

EID6414

In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC)

PMID 29848605 · Pal et al., 2018 · Open in CIViC

civic

Urothelial Carcinoma2
FGFR3 G370C	Erdafitinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID13179 In the randomized phase III THOR Cohort 1 trial of patients with advanced or metastatic urothelial carcinoma harboring selected FGFR alterations, FGFR3 G370C was a prespecified qualifying alteration. … (full text at CIViC) PMID 37870920 · Loriot et al., 2023 · Open in CIViC	civic
FGFR3 G370C	Erdafitinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID13176 In a bridging analysis of the phase 2 BLC2001 study of patients with metastatic or locally advanced, surgically unresectable urothelial carcinoma harboring FGFR alterations, 3 erdafitinib-treated pati… (full text at CIViC) PMID 32304281 · Wang et al., 2020 · Open in CIViC	civic

Urothelial Carcinoma2

FGFR3 G370C

Erdafitinib

Predictive

Supports Sensitivity Response

submitted

EID13179

In the randomized phase III THOR Cohort 1 trial of patients with advanced or metastatic urothelial carcinoma harboring selected FGFR alterations, FGFR3 G370C was a prespecified qualifying alteration. … (full text at CIViC)

PMID 37870920 · Loriot et al., 2023 · Open in CIViC

civic

FGFR3 G370C

Erdafitinib

Predictive

Supports Sensitivity Response

submitted

EID13176

In a bridging analysis of the phase 2 BLC2001 study of patients with metastatic or locally advanced, surgically unresectable urothelial carcinoma harboring FGFR alterations, 3 erdafitinib-treated pati… (full text at CIViC)

PMID 32304281 · Wang et al., 2020 · Open in CIViC

civic

Bladder Urothelial Papillary Carcinoma1unmapped disease
FGFR3 G370C	Erdafitinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID13180 In the randomized phase II THOR-2 Cohort 1 trial of patients with recurrent, bacillus Calmette-Guérin (BCG)-treated, high-risk, papillary-only non-muscle-invasive bladder cancer harboring select FGFR2… (full text at CIViC) PMID 37871701 · Catto et al., 2024 · Open in CIViC	civic

Bladder Urothelial Papillary Carcinoma1unmapped disease

FGFR3 G370C

Erdafitinib

Predictive

Supports Sensitivity Response

submitted

EID13180

In the randomized phase II THOR-2 Cohort 1 trial of patients with recurrent, bacillus Calmette-Guérin (BCG)-treated, high-risk, papillary-only non-muscle-invasive bladder cancer harboring select FGFR2… (full text at CIViC)

PMID 37871701 · Catto et al., 2024 · Open in CIViC

civic

Unmapped disease2unmapped disease
FGFR3 G370C	(functional)	Functional	D	Supports Gain Of Function	2	rejected	EID10414 1 patient's biopsy, which was the common soft subtype of keratinocytic epidermal nevi, displayed a double mutation of both FGFR3 G372C and G382R. The nevus from which the biopsy was taken displayed no… (full text at CIViC) PMID 16841094 · Hafner et al., 2006 · Open in CIViC	civic
FGFR3 G370C	(functional)	Functional	D	Supports Gain Of Function	2	submitted	EID13141 FGFR3 G370C was functionally evaluated in 293T, L8, and RCJ cells using chemical cross-linking, Western blotting, and c-fos luciferase assays. Compared with WT FGFR3, G370C demonstrated spontaneous li… (full text at CIViC) PMID 12009017 · Adar et al., 2002 · Open in CIViC	civic

Unmapped disease2unmapped disease

FGFR3 G370C

(functional)

Functional

Supports Gain Of Function

rejected

EID10414

1 patient's biopsy, which was the common soft subtype of keratinocytic epidermal nevi, displayed a double mutation of both FGFR3 G372C and G382R. The nevus from which the biopsy was taken displayed no… (full text at CIViC)

PMID 16841094 · Hafner et al., 2006 · Open in CIViC

civic

FGFR3 G370C

(functional)

Functional

Supports Gain Of Function

submitted

EID13141

FGFR3 G370C was functionally evaluated in 293T, L8, and RCJ cells using chemical cross-linking, Western blotting, and c-fos luciferase assays. Compared with WT FGFR3, G370C demonstrated spontaneous li… (full text at CIViC)

PMID 12009017 · Adar et al., 2002 · Open in CIViC

civic